|
|
|
|
| LEADER |
02956nmm a2200325 u 4500 |
| 001 |
EB000673214 |
| 003 |
EBX01000000000000000526296 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9783642759383
|
| 100 |
1 |
|
|a Domellöf, Lennart
|e [editor]
|
| 245 |
0 |
0 |
|a Drug Delivery in Cancer Treatment III
|h Elektronische Ressource
|b Home Care — Symptom Control, Economy, Brain Tumours
|c edited by Lennart Domellöf
|
| 250 |
|
|
|a 1st ed. 1990
|
| 260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 1990, 1990
|
| 300 |
|
|
|a VIII, 125 p. 8 illus
|b online resource
|
| 505 |
0 |
|
|a Perspectives in Home Care -- Symptom Control in Palliative Home Care -- Long Term and Home Parenteral Nutrition to Cancer Patients -- A Home-Care Project for Cancer Patients in Germany: Background and Experiences -- Economic Evaluation of Cancer Treatments -- Therapeutical Drug Monitoring of Anticancer Drugs -- Tumours in the Brain: A Special Case for Drug Delivery
|
| 653 |
|
|
|a Internal medicine
|
| 653 |
|
|
|a Internal Medicine
|
| 653 |
|
|
|a General Surgery
|
| 653 |
|
|
|a Pharmacology
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Surgery
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a ESO Monographs, European School of Oncology
|
| 028 |
5 |
0 |
|a 10.1007/978-3-642-75938-3
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-75938-3?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 520 |
|
|
|a The European School of Oncology came into existence to respond to a need for informa tion, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach wh ich is difficult for the Univer sities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monocional antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology
|